AbbVie Inc.
Compare market positioning with top industry peers
Explore AbbVie
Core profile pages, annual revenue records, and related research hubs for this company.
Acquisitions
4
Total Acquisitions
$102.8B
Disclosed Deal Value
2024
$10.1B
AbbVie acquired ImmunoGen to add Elahere and strengthen its antibody-drug conjugate and solid tumor oncology platform.
The deal gave AbbVie a commercial ovarian cancer medicine and additional ADC pipeline expertise.
Elahere became part of AbbVie's oncology revenue mix and expanded the company's position beyond hematologic oncology.
2024
$8.7B
AbbVie acquired Cerevel to deepen its neuroscience pipeline, especially emraclidine for schizophrenia and other clinical-stage assets.
The acquisition added potential next-decade neuroscience revenue opportunities alongside Vraylar, Botox Therapeutic, Ubrelvy, and Qulipta.
Cerevel increased AbbVie's long-term neuroscience optionality, with execution depending on clinical trial and regulatory outcomes.
2020
$63.0B
AbbVie acquired Allergan to add Botox, Juvederm, aesthetics, Vraylar, Ubrelvy, Qulipta, and other assets less tied to Humira.
The acquisition diversified AbbVie into aesthetics and expanded neuroscience, adding large brands and commercial channels.
Allergan became central to AbbVie's diversified post-Humira revenue base, though aesthetics demand can be more discretionary than core medicines.
2015
$21.0B
AbbVie acquired Pharmacyclics to add Imbruvica and build a stronger hematologic oncology business beyond Humira.
The deal gave AbbVie a major oncology product and helped diversify cash flow before Humira biosimilar pressure arrived.
Imbruvica became a meaningful oncology revenue contributor, though it later faced competitive pressure from newer BTK inhibitors.
AbbVie's growth strategy is to expand indications for Skyrizi and Rinvoq, defend Botox and aesthetics, invest in neuroscience and oncology, use targeted acquisitions to add late-stage assets, and maintain disciplined cash generation after Humira's decline.
AbbVie earns revenue from patented and specialty medicines sold globally through healthcare systems, insurers, distributors, specialists, hospitals, and aesthetics providers. Immunology is the largest segment, supported by neuroscience, oncology, aesthetics, eye care, and other therapeutics. AbbVie's business model is structured around leveraging high-margin, blockbuster specialty medicines to fund expansive research and development and aggressive strategic acquisitions. For years, this model was overwhelmingly reliant on Humira, the world's best-selling drug. However, anticipating the inevitable loss of exclusivity, AbbVie proactively evolved its business model through diversification. Today, the model relies on a balanced portfolio strategy spanning immunology (Skyrizi and Rinvoq), hematologic oncology (Imbruvica and Venclexta), neuroscience (Vraylar and Qulipta), and aesthetics (Botox and Juvederm). This diversified approach mitigates the risk associated with patent cliffs and generic competition. the inclusion of the aesthetics portfolio provides an unique, largely cash-pay revenue stream that is less susceptible to traditional pharmaceutical pricing pressures and government reimbursement constraints. The company continually reinvests its significant cash flow into targeted acquisitions and clinical partnerships, ensuring a steady pipeline of next-generation therapies to sustain long-term revenue growth and support a robust dividend return strategy for investors. This strategic alignment ultimately provides significant resilience against unforeseen market disruptions and generic pressures. AbbVie Inc., also known as AbbVie, is an American pharmaceutical company headquartered in North Chicago, Illinois. AbbVie produces drugs to treat a wide range of medical issues.
AbbVie Inc. has completed approximately 4 corporate acquisitions on record.
When evaluating M&A targets, AbbVie Inc. prioritizes complementary technology, specialized engineering talent, and immediate synergies that support workflow automation.
Acquisitions enable AbbVie Inc. to absorb critical capabilities faster than building in-house, accelerating its time-to-market across Biopharmaceutical.